ArticleThoracic cancer2022

Cost-effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non-small cell lung cancer.

Alessandra Buja et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.